Fenwick Takes Multiple Life Sciences Innovators Public

Fenwick’s capital markets and public companies group closed multiple initial public offerings in the last month for life sciences companies Stoke Therapeutics, Adaptive Biotechnologies and Morphic Holding.

The capital markets and public companies group, headed by corporate partners Robert Freedman and James Evans, represents leading technology and life sciences companies and underwriters in capital markets transactions.

The firm advised Stoke Therapeutics, a biotechnology firm developing therapies for genetic diseases, in its $163 million IPO. The team was led by partners Robert Freedman, Effie Toshav and Alan Smith.

In addition, Fenwick represented Morphic Holding, a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, in its $103.5 million IPO. Partners Robert Freedman and Effie Toshav led the team.

Fenwick also guided the underwriters in Adaptive Biotechnologies’ $345 million IPO. Adaptive Biotechnologies is a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient lives. The team was led by partners James Evans, Amanda Rose and Robert Freedman.

These wins underscore Fenwick’s leadership in the capital markets and life sciences space. The firm is regularly recognized as one of the top law firms for IPOs and currently ranks among the top two in the United States and in the top four worldwide for technology IPOs over $150 million, according to Dealpoint.​